Filed match against Actavis on October 15.

Patents. The lawsuit was filed beneath the provisions of the Hatch-Waxman Act, resulting in a stay of last FDA approval of Actavis' ANDA for 30 a few months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the problem before the courtroom, whichever occurs sooner, at the mercy of any other exclusivities.S. Sales of around $52 million, regarding to IMS Health data.. Actavis seeks FDA authorization to market generic edition of Quillivant XR Actavis plc today confirmed that it has filed an Abbreviated New Drug Software with the U.S. Continue reading